Zevra Therapeutics, Inc. (ZVRA)
AI stock analysis · as of Jul 26, 2026
Loading microstructure…
Zevra Therapeutics is a small-cap commercial-stage rare disease company whose core asset is MIPLYFFA (arimoclomol) for Niemann-Pick Type C, supplemented by a Phase 3 celiprolol program for vascular Ehlers-Danlos and legacy AZSTARYS royalties. FY2025 revenue surged to $106M with reported profitability, but this was heavily distorted by a $148M PRV sale in April 2025. The stock just fell ~24% after the EMA/CHMP issued a negative opinion on arimoclomol, effectively closing off the European NPC opportunity. The core question: does the intact U.S. MIPLYFFA ramp plus celiprolol optionality justify the current ~$563M market cap, or does the EU rejection permanently impair the multi-geography rare-disease thesis?
valuationFair-to-cheap on the surface (P/S 4.6x, forward P/E 8.4x, EV/EBITDA 28.5x) but the trailing metrics are distorted by the one-time PRV gain; on a normalized product-revenue basis (~$25-30M underlying MIPLYFFA run-rate) the ~$563M market cap implies ~18-22x product sales, which is reasonable for orphan drugs but no longer cheap given the EU opportunity has been eliminated.
This analysis is from Jul 26, 2026. Want the latest on ZVRA, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · MIPLYFFA U.S. ramp still early: 161 enrolled patients vs. estimated 300-350 diagnosed U.S. NPC population leaves meaningful headroom on an orphan-priced therapy
- · Balance sheet fortified by $148.3M net PRV proceeds (April 2025), providing runway to fund celiprolol Phase 3 and BD without immediate dilution
- · Celiprolol is the only Phase 3 candidate for vascular Ehlers-Danlos with no approved competitors — high-value optionality if DiSCOVER reads out positively
- · Sell-side is overwhelmingly constructive: 9 analysts, strong buy consensus, target mean $26.3 vs. spot $9.53 implies ~176% implied upside
- · Key_metrics show FY25 gross margin ~86% and reported ROE >100%; even excluding the PRV, MIPLYFFA product economics look attractive at orphan pricing
- · Elevated short interest (13.3% of float, 5.2 days to cover) plus deep post-selloff drawdown creates squeeze potential on any positive US commercial update
Bear case
- · EMA/CHMP negative opinion on arimoclomol eliminates the ~1,100-patient European NPC opportunity that was a core growth driver in the 10-K thesis
- · Revenue base is dangerously concentrated: MIPLYFFA is essentially the only commercial product (OLPRUVA generated just $0.8M in 2025 and is being deprioritized)
- · Reported FY25 profitability is a mirage — driven by the one-time $148M PRV sale; underlying operations remain FCF-negative (latest FCF -$2.4M) with recurring operating losses historically
- · Competitive pressure from IntraBio's AQNEURSA (approved shortly after MIPLYFFA) in an already ultra-small NPC patient pool of only 300-350 U.S. patients
- · AZSTARYS royalty stream is in active dispute with Commave, threatening a key non-dilutive cash source and up to $420M in remaining milestones
- · DiSCOVER Phase 3 for celiprolol was only 52/150 patients enrolled at year-end — event-driven trial timing risk means catalyst could slip well beyond 2026
- · Sole-source API/drug product supplier with no internal manufacturing creates supply chain fragility for the sole commercial franchise
Catalysts
- · Q2 2026 earnings call on August 5, 2026 — key for MIPLYFFA U.S. enrollment/revenue trajectory and EU strategy post-CHMP
- · Potential EMA appeal or re-examination of the CHMP arimoclomol opinion
- · DiSCOVER Phase 3 celiprolol enrollment progress updates and interim event triggers
- · Resolution or escalation of the Commave/AZSTARYS royalty dispute
- · Short squeeze potential: 13.3% short interest and 5.2 days to cover could amplify any positive commercial or regulatory update
- · Announced BD/inorganic pipeline additions leveraging PRV cash and existing rare-disease commercial infrastructure
Key risks
- · Further MIPLYFFA competitive share loss to AQNEURSA in an already tiny addressable market
- · Celiprolol Phase 3 failure or multi-year delay — this is the primary pipeline optionality
- · Cash burn resumes materially post-PRV; company has history of tapping capital markets and could dilute existing holders
- · Loss of AZSTARYS royalty/milestones if Commave dispute goes against Zevra
- · Manufacturing disruption at sole-source API/drug product supplier could halt MIPLYFFA sales
- · Institutional ownership at 73.5% means any concentrated exit would exacerbate volatility
What to watch
- · Q2 2026 earnings call on August 5, 2026 — MIPLYFFA enrollment count vs. the 161 baseline
- · Any EMA re-examination filing or updated European strategy commentary
- · Celiprolol DiSCOVER enrollment progression toward 150-patient target
- · Cash burn cadence now that PRV proceeds are in — first look at organic run-rate
- · $7.16 52-week low as key technical support; $15.03 52-week high as resistance
- · Short interest updates — 13.3% float short with 5.2 days to cover is squeeze-eligible on positive news
Key metrics
Price target rationale
Base case ~$14 applies ~6-7x normalized U.S.-only MIPLYFFA revenue plus modest credit for celiprolol optionality and net cash. Bull case ~$22 assumes accelerated U.S. NPC penetration, successful CHMP re-examination, and positive celiprolol enrollment cadence. Bear case ~$6 reflects competitive share loss to AQNEURSA, Commave dispute loss, and eventual dilution to fund operations as cash burn resumes.
On Wall Street's view (mixed): The $26.33 consensus target predates the CHMP negative opinion and almost certainly overstates fair value now that EU revenue is off the table; while U.S. MIPLYFFA and celiprolol optionality justify upside from the post-selloff level, expecting a triple from here requires stale assumptions on European approval.
Latest filing (10-K)
Zevra is a newly commercial rare disease company whose entire investment thesis rests on MIPLYFFA's ability to capture the tiny NPC market, backstopped by a $148M PRV windfall and a high-risk Phase 3 bet on celiprolol for VEDS.
Zevra Therapeutics is a commercial-stage rare disease company that generates revenue primarily from sales of MIPLYFFA (arimoclomol) for Niemann-Pick disease type C and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders, both sold in the U.S. through a specialty pharmacy. The company also earns royalties and milestones from its partnered ADHD product AZSTARYS, licensed to Commave/Corium. A one-time $148.3 million windfall from selling a rare pediatric disease priority review voucher received upon MIPLYFFA's FDA approval dominated 2025 cash flows.
What the news says · bearish
The dominant storyline for ZVRA is a sharp single-day selloff of 20-23% triggered by the EMA's CHMP issuing a negative opinion on arimoclomol for Niemann-Pick Type C disease, effectively blocking a European marketing authorization. This is a meaningful pipeline setback for a rare-disease biotech that had been building momentum, as reflected in the pre-event bullish coverage citing patent extensions and analyst upside targets. Management is attempting to soften the blow by pledging patient access support, and at least one analyst frames the EU rejection as 'a headwind, but not insurmountable,' suggesting the US commercial story remains intact. However, the scale of the selloff and multiple bearish data points from institutional flow trackers indicate the market is repricing EU revenue expectations significantly, and near-term sentiment is firmly negative pending the Q2 2026 earnings call for further clarity.
This analysis is from Jul 26, 2026. Markets move. Get the current read on ZVRA and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.